DEA Addiction Medicine Essentials
OVERVIEW:
This course provides an in-depth understanding of the neurobiology of addictions and the assessment, diagnosis, and medical management of substance use disorders. Participants will learn about the prevalence and consequences of cannabis, stimulant, opioid, and alcohol use disorders. The course will also cover the management of withdrawal from opioids, alcohol, and benzodiazepines.
Speakers:
Anthony Dekker, DO, FAOAAM; Julie Kmiec, DO, FAOAAM; R. Gregory Lande, DO, FAOAAM; Stephen Wyatt, DO, FAOAAM; Veronica Ridpath, DO
OBJECTIVES:
Give an overview of the neurobiology of addiction and how it affects the neuroplastic changes in the brain
Screen patients with substance use disorders and provide appropriate treatment
Recognize the prevalence and consequences of cannabis use disorder and its impact on patients' medical and social well-being
Identify and manage patients with stimulant use disorder and discuss DSM-5 criteria diagnosis
Describe the value of using medication-assisted treatment to help patients with opioid use problems
Identify high-risk factors of patients who are candidates for naloxone
Discuss developmental components of managing patients with alcohol use disorder and commonly used medication-assisted withdrawal techniques
DEA TRAINING FULFILLMENT:
This course satisfies the eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners on the treatment and management of patients with opioid or other substance use disorders (SUDs).
Expiration Date:
June 16, 2026
The AOA designates this activity for a maximum of 8.0
AMA PRA Category 1 Credits
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AOAAM designates this activity for a maximum of 8.0 AOA Category 1-A Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly sponsored by the AOA and the AOAAM.